A coupled in vitro protein-synthesizing system has been developed with components derived totally from Bacillus subtilis. The system synthesized specific gene products from various exogenous DNA templates, including B. subtilis phage 4o29, plasmid pUB110, and a heterologous B. subtilis-Escherichia coli gene fusion containing the transposon Tn9-derived chloramphenicol acetyltransferase (cat) gene. The gene fusion product was able to show CAT activity, bind specifically to a Sephacryl-chloramphenicol column, and react immunologically against anti-CAT antiserum. The fidelity of this in vitro system was demonstrated by the synthesis of gene products identical to that made in vivo. We suggest that this system may be used to study the regulation of gene expression in vitro.To study the regulation of gene expression in Bacillus subtilis, it is desirable to develop a coupled in vitro proteinsynthesizing system derived totally from this organism. The differences in promoters, transcriptional apparatus, transcriptional regulatory mechanisms (7), and translation signals and machinery (19,26,27,30,31) between grampositive and gram-negative organisms invalidate the use of the Escherichia coli or any other heterologous in vitro protein-synthesizing system in the analysis of gene expression in B. subtilis.Thus, although several in vitro protein-synthesizing systems have been described for several Bacillus species (3,6,13,18,20), these systems used mainly synthetic, endogenous, or exogenous RNA as the translational template. These systems also used several components or fractions derived from E. coli, which could not only complicate the interpretation of the results but also lead to faulty conclusions.To overcome these difficulties, we have developed a DNA-directed cell-free protein-synthesizing system that is derived totally from B. subtilis. This system contains readily prepared components, takes advantage of added RNA polymerase and tRNA prepared from B. subtilis, and is effective in terms of rate and specificity of synthesis.This system was able to synthesize an active enzyme by use of one of the transposon Tn9-derived chloramphenicol acetyltransferase (cat) gene fusions, pGR71-43, as the DNA template (9, 10). Furthermore, the product was characterized by its electrophoretic mobility on polyacrylamide gels, its binding characteristics to a specific affinity column, and its interaction with anti-CAT antiserum.MATERIALS AND METHODS Bacterial strains and media. B. subtilis 168 cells grown in superrich medium (11) were used to prepare the components for the in vitro system. E. coli HB101 cells carrying plasmid pBR328 were used to purify CAT (28).Preparation of nucleic acids. Plasmid pGR71 and its derivatives were purified by the procedure described by Lovett